Twist Bioscience Corporation $TWST Shares Newly Bought by Veracity Capital LLC

Veracity Capital LLC bought a new position in Twist Bioscience Corporation (NASDAQ:TWST) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 3,755 shares of the company’s stock, valued at approximately $726,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. bought a new stake in shares of Twist Bioscience during the second quarter valued at approximately $600,191,000. William Blair Investment Management LLC bought a new position in Twist Bioscience in the 2nd quarter valued at approximately $223,722,000. Bank of America Corp DE purchased a new stake in Twist Bioscience during the 2nd quarter valued at $94,922,000. Allspring Global Investments Holdings LLC bought a new stake in shares of Twist Bioscience in the 1st quarter worth $22,563,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Twist Bioscience in the second quarter worth $19,722,000.

Insider Buying and Selling

In other Twist Bioscience news, insider Dennis Cho sold 9,514 shares of the company’s stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total value of $1,797,004.32. Following the completion of the transaction, the insider directly owned 63,789 shares in the company, valued at $12,048,466.32. This represents a 12.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Adam Laponis sold 8,057 shares of the firm’s stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total transaction of $1,521,806.16. Following the sale, the chief financial officer owned 100,576 shares in the company, valued at $18,996,794.88. The trade was a 7.42% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 599,458 shares of company stock worth $93,383,392 in the last ninety days. Corporate insiders own 3.08% of the company’s stock.

Twist Bioscience Stock Performance

TWST stock traded down $6.79 during midday trading on Thursday, reaching $148.85. 2,296,151 shares of the company’s stock traded hands, compared to its average volume of 1,684,040. The stock’s 50-day moving average is $141.74 and its 200 day moving average is $95.17. The stock has a market cap of $9.33 billion, a P/E ratio of -67.25 and a beta of 2.19. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $219.71. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The company had revenue of $118.38 million during the quarter, compared to the consensus estimate of $114.55 million. During the same period in the prior year, the business posted $0.33 earnings per share. Twist Bioscience’s revenue for the quarter was up 23.2% compared to the same quarter last year. As a group, analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently commented on TWST. Jefferies Financial Group initiated coverage on Twist Bioscience in a report on Thursday. They issued a “hold” rating and a $150.00 price objective for the company. Evercore downgraded shares of Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price target on the stock. in a report on Monday, July 6th. Piper Sandler lifted their price target on shares of Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 5th. Canaccord Genuity Group boosted their price objective on shares of Twist Bioscience from $90.00 to $120.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Finally, BWS Financial restated a “sell” rating and issued a $45.00 target price on shares of Twist Bioscience in a report on Friday, September 18th. Eight analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $128.17.

Twist Bioscience Company Profile

Twist Bioscience Corporation (NASDAQ:TWST) is a biotechnology company that develops and manufactures synthetic DNA using a silicon-based production platform. Its technology is designed to enable the precise, high-throughput synthesis of DNA at smaller scale and with potentially lower material consumption than traditional methods.

The company provides synthetic DNA products and services for applications in drug discovery and development, biotechnology research, agriculture, industrial chemicals and other life sciences markets.